Status:

TERMINATED

Bronchial Hyper-responsiveness in Reflux Cough

Lead Sponsor:

Hull University Teaching Hospitals NHS Trust

Conditions:

Cough

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The study aim is to determine the effect of 8 weeks of anti-reflux treatment (full acid suppression) on bronchial hyper-responsiveness and whether there is a symptomatic improvement.

Eligibility Criteria

Inclusion

  • Positive methacholine challenge test PC20 less than 4mg/ml (Can be previously documented in patients notes within last 4weeks)
  • Written informed consent
  • Patients with a history of chronic cough (at least 3 months duration), and associated symptoms of gastro-oesophageal reflux
  • Male and female subjects of at least 18 yrs of age
  • Subjects able to perform satisfactory FEV1 manoeuvres
  • Subjects able to understand the study and co-operate with the study procedures
  • Subjects who consent to their general practitioner (GP) being informed of their study participation

Exclusion

  • has had a heart attack in the last three months
  • suffers from angina, hypertension or ischaemic heart disease
  • has epilepsy for which he/she is taking medication
  • FEV1\< 60% predicted
  • FEV1\<1.6L
  • Female subjects who are pregnant, or lactating, or who are of child bearing potential but are not using contraceptive measures
  • Suffering from any concomitant disease which may interfere with study procedures or evaluation.
  • A lower respiratory tract infection 4 weeks prior to entry on to study
  • Participation in another study (use of investigational product) within 30 days preceding entry on to study.
  • Alcohol or drug abuse
  • Use of opiates to treat cough 1 week prior to enrollment
  • Subjects who are taking Angiotensin Converting Enzymes (ACE) inhibitors.
  • Subjects who have significant pathology on most recent chest X-Ray.
  • Inability to understand the procedures and the implications of a challenge test
  • Patients already taking or have taken in last 4 weeks PPI and H2 receptor antagonist (full acid suppression treatment

Key Trial Info

Start Date :

September 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT00668317

Start Date

September 1 2006

End Date

January 1 2010

Last Update

July 23 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Trials Unit , Cardiovascular and respiratory studies, Castle Hill Hospital

Cottingham, East Yorkshire, United Kingdom, HU16 5JQ